Liver Metastasectomy and Systemic Therapy Improve Overall Survival Compared With Surgery Alone After Curative Liver Resection of Colorectal Metastases in a Developing Country (Costa Rica)

Background Resection of liver-isolated metastases of colorectal cancer (CRC) offers the greatest likelihood of cure. Nevertheless, recurrence rates after this procedure are high, and chemotherapy is a reasonable choice with inconclusive evidence. We aimed to determine if there is a survival difference between patients receiving systemic therapy with surgery versus surgery alone for resection of liver metastases.

Methods From a source population of 170 patients treated in our National Centre (Centro Nacional de Cirugía Hepatobiliar, San José, Costa Rica), with liver metastases from various primary sites, we selected 51 patients with CRC who underwent hepatic resection with curative intent. We categorized patients according to the treatment received (fluoropyrimidine-based chemotherapy plus or minus monoclonal antibody and surgery vs surgery alone) and then calculated the overall survival (OS) rate according to the Kaplan-Meier method. A Cox proportional hazard model was used to assess the influence of potential confounding variables on OS.

Results After a median follow-up of 41.6 months, OS was significantly better for patients treated with systemic therapy (before and/or after hepatic resection) versus surgery alone (3-year OS: 66.7% vs 41.7%; hazard ratio, 0.37; 95% CI, 0.15 to 0.91; log-rank test: P = .025). There were no differences among patients who underwent neoadjuvant (48.7%), perioperative (46.2%), and adjuvant therapy (5.1%). The use of systemic therapy was significantly associated with better OS after adjustment for confounding variables (hazard ratio, 0.23; 95% CI, 0.07 to 0.92; P = .03).

Conclusion Our findings support the use of systemic therapy (either perioperative, neoadjuvant, or adjuvant) as part of isolated hepatic metastasectomy from CRC.
shown some efficacy in patients with resectable liver metastases, the indication of systemic therapy after curative surgery for liver metastases is currently uncertain. There are contradictory results in the literature as the result of scarce data and trials that closed prematurely because of slow accrual. Hence, clear evidence for a survival benefit of systemic treatment compared with observation alone has not been well established. Nevertheless, a recent meta-analysis of randomized and observational clinical trials showed a clinical benefit in terms of overall survival (OS) and recurrence-free survival for those patients who underwent hepatic metastasectomy and received systemic chemotherapy.

Furthermore, there is a current debate about the preference of neoadjuvant, perioperative, or adjuvant treatment in these patients, and the best regimen remains to be determined. Moreover, there are scarce data regarding this procedure in developing countries, where access to medical care is often limited.

In this retrospective study, we aimed to determine if patients receiving any kind of systemic therapy plus surgery obtain a better OS than patients treated with surgery alone for CRC liver metastases.

METHODS

Between January 2009 and December 2014, we reviewed the clinical records of 170 patients treated in the National Centre of Hepatobiliary Surgery (San José, Costa Rica) who underwent hepatic metastasectomy. We then selected 51 patients who underwent curative hepatic resection of colorectal metastases. The attending surgeon performed the surgical procedure (metastasectomy, segmentectomy, or partial hepatectomy) after multidisciplinary planning. Patients were considered candidates for this approach if they had no significant medical condition that contraindicated the surgical procedure, an Eastern Cooperative Oncology Group performance status score ≤ 2, and no detectable extrahepatic tumor.

The follow-up consisted of clinical evaluation performed at least every 6 weeks during the first year and at least every 3 months thereafter. Evaluation included physical examination, serum carcinoembryonic antigen levels, and at least three annual thorax and abdomen computed tomography scans or an abdominal ultrasound every 4 or 6 months. Patients received conversion (ie, neoadjuvant), perioperative, adjuvant, or no systemic therapy, according to the recommendation of the multidisciplinary team. For the purpose of this work, we considered conversion (neoadjuvant) chemotherapy solely as the administration of preoperative treatment for resectable or borderline-resectable liver metastases. The administration of chemotherapy before and after the surgical procedure was considered perioperative treatment. Lastly, adjuvant therapy refers to systemic treatment received after surgical resection.

The tumor board decided upon the most suitable chemotherapeutic regimen (fluoropyrimidine based) with or without the addition of any monoclonal antibody (bevacizumab or cetuximab). Individual patient data were collected, including age, sex, tumor stage and grade, as well as primary site, number, and size of liver metastases.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Because of the retrospective nature of this study, formal consent was not required.

Categorical variables are presented as percentages and were compared by the \( \chi^2 \) test or Fisher’s exact test when applicable. Continuous variables are presented as the mean ± standard deviation and were analyzed by the Mann-Whitney U test as appropriate. Follow-up time was calculated as the time from surgery to death or to August 1, 2014. Disease-free survival (DFS) and OS were calculated using the Kaplan-Meier method, measuring time from the date of surgery to the date of failure at any site (determined by RECIST 1.1) or to the date of death from any cause, respectively. Using the log-rank test, we compared patients who received systemic treatment plus surgery with those who underwent only the surgical procedure. The Cox proportional hazards regression model was used to calculate crude hazard ratios.

A \( P \) value < .05 was considered statistically significant. Data were analyzed using SPSS for Mac version 20.0 (SPSS, Chicago, IL).

RESULTS

Patients had a median follow-up of 41.6 months (interquartile range: 29.2 to 44.4 months). Patient demographics and clinical variables stratified according to treatment received are presented in Table 1. Treatment modalities were as follows: neoadjuvant therapy (conversion therapy), 19 patients (48.7%); perioperative chemotherapy, 18 patients (46.2%); and adjuvant therapy, two patients (5.1%). The regimen used most frequently was capecitabine plus oxaliplatin (XELOX)
in 20 patients; followed by fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6) plus bevacizumab in nine patients. Other regimens were as follows: FOLFOX-6 in three patients; fluorouracil, leucovorin, and irinotecan (FOLFIRI) in three patients; XELOX plus cetuximab in one patient; and capecitabine alone in the remaining patient.

The majority of surgical procedures consisted of segmentectomy or tumorectomy (in 28 patients); partial hepatectomy was performed in the remaining cases. Seven patients also received radiofrequency ablation of suspected lesions. All of the procedures were done with curative intent. Only five patients (10%) presented with surgical complications, including infection or bleeding. None of these cases were fatal.

The median OS for all patients was 41.8 months (95% CI, 39.25 to 44.36). As depicted in Figure 1, patients who received systemic therapy had a median OS of 44.4 months (95% CI, 39.47 to 44.36) compared with 36.3 months (95% CI, 21.12 to 51.48) for patients who underwent surgery alone (*P* = .025). The 3-year OS rate was 41.7% in patients treated with surgery alone versus 66.7% in those who also received systemic treatment. There were no statistically significant differences among any of the systemic treatment modalities (neoadjuvant, perioperative, or adjuvant; *P* = .91).

During the follow-up period, 36 patients (70.6%) had relapses, and 29 patients (83%) had recurrences confined to the liver. Among these patients, a second metastasectomy followed by fluoropyrimidine-based chemotherapy was

---

**Table 1 – Clinical Characteristics of the Studied Population According to Treatment Received**

| Variable | Patients (n = 51) | Surgery Only (n = 12) | Systemic Treatment and Surgery (n = 39) | *P* |
|----------|------------------|----------------------|---------------------------------------|-----|
| Male sex, No. (%) | 39 (76.5) | 7 (58.3) | 32 (82.1) | .09 |
| Age, years (mean ± SD) | 61.72 ± 14.5 | 63.83 ± 19.7 | 61.07 ± 12.8 | .90 |
| T (primary site), No. (%) | 69 | 2 (5.1) | 2 (5.1) | |
| T1 | 3 (5.9) | 1 (8.3) | 2 (5.1) | |
| T2 | 8 (15.7) | 2 (16.7) | 6 (15.4) | |
| T3 | 33 (64.7) | 7 (58.3) | 26 (66.7) | |
| T4 | 7 (13.7) | 2 (16.7) | 5 (12.8) | |
| N (primary site), No. (%) | 95 | 2 (5.1) | 9 (23.1) | |
| N0 | 3 (5.9) | 1 (8.3) | 2 (5.1) | |
| N1 | 12 (23.5) | 3 (25) | 9 (23.1) | |
| N2 | 15 (29.4) | 3 (25) | 12 (30.8) | |
| Nx (fewer than 12 harvested nodes) | 10 (19.6) | 2 (16.7) | 8 (20.5) | |
| Unknown | 11 (21.6) | 3 (25) | 8 (20.5) | |
| Clinical stage (%) | 76 | 2 (5.1) | 27 (69.2) | |
| II | 3 (5.9) | 1 (8.3) | 2 (5.1) | |
| III | 20 (39.2) | 10 (83.3) | 10 (25.6) | |
| IV | 28 (54.9) | 1 (8.3) | 27 (69.2) | |
| Primary origin (%) | 54 | 21 (53.8) | 18 (46.2) | |
| Colon | 27 (52.9) | 6 (50) | 21 (53.8) | |
| Rectum | 24 (47.1) | 6 (50) | 18 (46.2) | |
| Synchronicity of liver metastases (%) | <.001* | 28 (54.9) | 27 (69.2) | |
| Synchronous | 28 (54.9) | 1 (8.3) | 27 (69.2) | |
| Methacronous | 23 (45.1) | 11 (91.7) | 12 (30.8) | |
| Mean size of liver metastases (cm) | .87 | 3.01 ± 1.8 | 3.19 ± 1.5 | |
| More than three hepatic lesions (%) | .13 | 13 (28.9) | 12 (30.8) | |
| Incomplete resection rate (R1; %) | .63 | 7 (13.7) | 5 (12.8) | |
| Recurrence proportion after metastasectomy during follow-up | .23 | 36 (70.6) | 26 (66.7) | |
| | | 10 (83.3) | | |

*Statistically significant at *P* < .05.
performed in eight cases, and the remaining patients received systemic chemotherapy. Only five patients could not receive further therapy due to a poor performance status score.

Figure 2 shows the probability of DFS according to treatment received. There were no significant differences between surgery-only patients and those who also received systemic therapy ($P = .20$).

DISCUSSION

The survival benefit from complete hepatic resection in patients with limited liver metastases from CRC is well established. Nevertheless, the role of systemic therapy following metastasectomy is currently under debate. Two randomized trials have shown a significant improvement in progression-free survival (as the primary end point) in patients receiving chemotherapy versus observation alone after hepatic resection. Both these trials were prematurely closed because of slow accrual; however, the pooled analysis of these trials showed a nonsignificant trend toward better OS in patients receiving adjuvant therapy. On the other hand, the EORTC (European Organization for Research and Treatment of Cancer) 40983 trial did not find any survival benefit after a median follow-up of 8.5 years in patients treated with perioperative FOLFOX4 compared with patients who underwent surgery alone, even when the 3-year progression-free survival increased to an absolute risk of 9.2% in patients who underwent resection.

In our retrospective study, we demonstrate that patients receiving systemic therapy had a better 3-year OS than patients who underwent surgery alone, regardless of the regimen (neoadjuvant, perioperative, or adjuvant). Furthermore, our results are from a real-world setting, showing the clinical efficacy and good outcomes of this treatment modality (ie, the use of systemic therapy and resection of liver metastases).

The discrepancies between our data and those from previous clinical trials could be the result of different regimens used or of different patient populations. For example, among patients in the EORTC 40983 trial, 66% had metachronous disease, whereas the majority of our patients had synchronous metastases. In fact, previous studies have demonstrated that patients with metachronous liver metastases have a poor OS compared with patients diagnosed with synchronous disease. Because the vast minority of our patients with metachronous metastases did not receive systemic treatment, we cannot conclude that there was any real therapeutic benefit of this approach in this particular subgroup. Nevertheless, other authors have also shown the absence of DFS and OS benefit in patients treated with adjuvant FOLFOX after resection of metachronous liver metastases, whereas other authors have shown some efficacy of medical treatment in this subgroup.

In our study, we found that the relapse rate (70.6%) was similar to that reported previously in the literature. It makes it reasonable to administer systemic treatment to these patients to increase DFS and eventually to improve OS. However, we did not find any significant differences among patients...
according to treatment received in terms of DFS. This could be attributed to a type II error, because our sample size was small and the study’s design was retrospective. Despite these caveats and the low statistical power, we did find a significant difference in OS among patients treated with surgery alone versus those who received any systemic treatment modality before and/or after metastasectomy. These results are in agreement with a recent meta-analysis that showed a 23% improvement in OS among patients treated with liver metastasectomy plus chemotherapy, regardless of the timing of administration.6

Our study does have some limitations. The small sample size and the retrospective design of this study could overestimate the magnitude of the reported outcomes.15 Similarly, selection bias was likely to occur as a result of the nonrandomized selection of the included patients and the retrospective nature of our data.

There are scarce data related to this procedure in Latin American countries. Indeed, the majority of trials have been conducted in developed regions with different ethnic populations. Our results contribute to current evidence supporting the use of systemic therapy as part of the management of patients with resectable liver metastases, although a prospective clinical trial is needed to better clarify this approach.

In summary, our findings support the indication of systemic therapy before and/or after resection of CRC liver metastases because of its significant OS benefit in a real-world population.

DOI: 10.1200/JGO.2016.003285
Published online on jgo.org on May 4, 2016.

AUTHOR CONTRIBUTIONS
Conception and design: All authors
Administrative support: Paula Quesada-Soto, Allan Ramos-Esquivel
Collection and assembly of data: Paula Quesada-Soto, Denis Landaverde
Data analysis and interpretation: Allan Ramos-Esquivel
Manuscript writing: All authors
Final approval of manuscript: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Paula Quesada-Soto
No relationship to disclose

Denis Landaverde
No relationship to disclose

Allan Ramos-Esquivel
No relationship to disclose

REFERENCES
1. Van Cutsem E, Cervantes A, Nordlinger B, et al: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1-iii9, 2014
2. Morris EJ, Forman D, Thomas JD, et al: Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97:1110-1118, 2010
3. Petrelli NJ: Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol 26:4862-4863, 2008
4. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 26:4906-4911, 2008
5. Wieser M, Sauerland S, Arnold D, et al: Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer 10:309, 2010
6. Araujo RL, Günen M, Herman P: Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: Systematic review and meta-analysis. Ann Surg Oncol 22:3070-3078, 2015
7. Hsu HC, Chou WC, Shen WC, et al: Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer. Anticancer Res 33:3317-3325, 2013
8. Kim SY, Kim HJ, Hong YS, et al: Resected colorectal liver metastases: Does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol 100:713-718, 2009
9. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683, 2009
10. Gallinger S, Biagi JJ, Fletcher GG, et al: Liver resection for colorectal cancer metastases. Curr Oncol 20:e255-e265, 2013
11. Portier G, Elias D, Bouche O, et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976-4982, 2006

12. Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208-1215, 2013

13. Nozawa H, Kitayama J, Sunami E, et al: FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. Oncology 80:84-91, 2011

14. Liu JH, Hsieh YY, Chen WS, et al: Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis 25:1243-1249, 2010

15. Ioannidis JP: Why most discovered true associations are inflated. Epidemiology 19:640-648, 2008